Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COSTEM 2019 | Should upfront CAR-T be part of the early MM treatment?

Philip McCarthy • 26 Oct 2019
COSTEM 2019
Multiple Myeloma Antibodies CAR-T Daratumumab
Bluebird

Philip McCarthy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses whether upfront CAR-T cell therapy should be part of the early MM treatment. BCMA, MRD and antibody-drug conjugates are also discussed. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Philip McCarthy

Treatment-free intervals: what is best for patients? 4:02
Treatment-free intervals: what is best for patients?
Philip McCarthy • 1 Sep 2021
Future maintenance therapy approaches for multiple myeloma 4:22
Future maintenance therapy approaches for multiple myeloma
Philip McCarthy • 1 Sep 2021
CAR-T for myeloma: where are we now and where are we going? 5:15
CAR-T for myeloma: where are we now and where are we going?
Philip McCarthy • 1 Sep 2021
Does maintenance therapy increase overall survival in myeloma? 10:09
Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer et al. • 13 Sep 2019

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals